Influenza, zoster, hepatitis A, hepatitis B, and the diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP) are among the most common vaccines involved in medication errors in the United States, according to a new report from the Institute for Safe Medication Practices (ISMP). The other most common problematic vaccines include Haemophilus influenzae type b conjugate, Tdap, DTaP-IPV, human papillomavirus (HPV4), and measles, mumps, rubella, and varicella (MMRV).
Influenza, zoster, hepatitis A, hepatitis B, and the diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP) are among the most common vaccines involved in medication errors in the United States, according to a new report from the Institute for Safe Medication Practices (ISMP). The other most common problematic vaccines include Haemophilus influenzae type b conjugate, Tdap, DTaP-IPV, human papillomavirus (HPV4), and measles, mumps, rubella, and varicella (MMRV).
ISMP, which established the ISMP National Vaccine Errors Reporting Program with the California Department of Health in September, 2012, also found that unfamiliarity with the vaccine and mistakes in choosing age-dependent formulations of vaccines are among the most common factors in vaccine errors.
The other common contributing factors associated with vaccine errors include: failure to check or verify the patient’s age, health record, or state registry; similar vaccine names and abbreviations; similar and confusing vaccine labeling and packaging, unsafe storage conditions; and expiration dates not noticed or misunderstood.
“While the immediate impact of a vaccine-related error on a patient may not be serious, such errors may render the vaccine ineffective or reduce its effectiveness, leaving patients unprotected against serious diseases…,” ISMP wrote in the March 13, 2014, edition of ISMP MedicationSafetyAlert!
While vaccine errors are prevalent, the ISMP provides a number of recommendations for practitioners to safely administer vaccines. They include:
View the full list of ISMP’s recommendations for avoiding vaccine administration errors at: http://www.ismp.org/newsletters/acutecare/issues/20140313.pdf.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More